Avivagen Inc.

Equities

VIV

CA05382F2026

Fishing & Farming

Delayed Toronto S.E. 09:30:00 2024-03-05 am EST 5-day change 1st Jan Change
0.005 CAD 0.00% Intraday chart for Avivagen Inc. 0.00% 0.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Avivagen Inc. Announces New 500 Kg Order for OxC-beta CI
Avivagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
Avivagen Brief: Announcing several corporate updates, relating to allowances of patents, a waiver of an interest payment on its senior secured debentures and continuation of the strategic review process MT
Avivagen Secures New Orders for 1.1 Tons of Oxc-Beta Livestock Product MT
Avivagen Announces New Orders for 1.1 Tonnes of Oxc-Beta? Livestock Product CI
Avivagen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023 CI
Avivagen Reports Increase in Sales to Existing Customer MT
Avivagen Inc. Announces Significant Increase in Sales to an Existing Customer CI
Avivagen Brief: Announcing "Significant" Increase in Sales to an Existing Customer MT
Avivagen Launches Strategic Review; Comes After Soaring 50% Yesterday MT
Avivagen Brief: Announcing Review of Strategic Alternatives MT
Avivagen Announces Review of Strategic Alternatives CI
Avivagen Inc. Announces Board Changes CI
Avivagen Narrows Fiscal Q1 Loss, Revenue Falls; Says Will Need Cash Proceeds to Continue as Going Concern MT
Avivagen Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023 CI
Avivagen Inc. Reports Earnings Results for the Full Year Ended October 31, 2022 CI
Avivagen Inc. Auditor Raises 'Going Concern' Doubt CI
Avivagen Announces Foundational Scientific and Commercial Evidence of Product Published in Peer-Reviewed Journal MT
Avivagen Details Securities for Service Agreements with CEO and Chief Scientific Officer MT
Avivagen Inc. announced that it expects to receive CAD 1 million in funding CI
Avivagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022 CI
Avivagen Inc. Appoints Ira Levy as Interim CFO CI
Avivagen Brief: Adds It "Supports Wide-spread Adoption of the Technology around the World" MT
Avivagen Brief: Says Publication of Scientific Paper on Safety of Oxidized Beta Carotene is a "Milestone on the path to broader regulatory clearance to market and sell OxC-beta Products in the U.S." MT
Avivagen Brief: Announced Publication of Peer-Reviewed Article in Food and Chemical Toxicology Journal MT
Chart Avivagen Inc.
More charts
Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.
More about the company
  1. Stock
  2. Equities
  3. Stock Avivagen Inc. - Toronto S.E.
  4. News Avivagen Inc.
  5. Avivagen : Raising C$5 Million in Bought-Deal Offering of Share Units